SB 4 (Eticovo)|CAS 100874-08-6|DC Chemicals

Cas No.:	100874-08-6
Chemical Name:	2-(4-Bromobenzylsulfanyl)benzoxazole
Synonyms:	BMP signaling agonist sb4;2-(4-Bromobenzylsulfanyl)benzoxazole;2-[(4-bromophenyl)methylsulfanyl]-1,3-benzoxazole;SB 4;HMS1585K19;2-((4-Bromobenzyl)thio)benzo[d]oxazole;2-[(4-bromophenyl)methylthio]benzoxazole;ST50478260;2-[[(4-Bromophenyl)methyl]thio]benzoxazole
SMILES:	BrC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])SC1=NC2=C([H])C([H])=C([H])C([H])=C2O1
Formula:	C₁₄H₁₀BrNOs
M.Wt:	320.204301357269
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes; increases the phosphorylation of key second messengers (SMADs-1/5/9) and also increased expression of direct target genes (inhibitors of DNA binding, ID1 and ID3) in canonical BMP signaling.
Target:	IC50: BMP4 signal[1]
In Vitro:	BMP signaling agonist sb4 (0.05 μM-1 μM; 24 hours) induces phosphorylated SMAD-1/5/9 in a dose-dependent manner in PRECs cells under serum-starved conitions[1]. BMP signaling agonist sb4 (1 μM; 0-60 mins) enhances the efficacy of signaling at each concentration of rhBMP4 tested. This effect is most pronounced at low concentrations of rhBMP4, whereby sb4 increases BRE-luc expression 2-fold at 0.4 ng/ml of rhBMP4[1]. Western Blot Analysis[1] Cell Line: Primary mouse kidney epithelial cells (PRECs) Concentration: 0.05 μM-1 μM Incubation Time: 24 hours Result: Incresed p-SMAD-1/5/9 abundance in PRECs. Western Blot Analysis[1] Cell Line: BRE-Luc cells Concentration: 1 μM Incubation Time: 0min, 5 mins, 15 mins, 30 mins, 45 mins, 60 mins Result: Acted to stabilize p-SMAD-1/5/9 to enhance the transcriptional response.
References:	[1]. Bradford STJ, et al. High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole compounds.J Biol Chem. 2019 Mar 1;294(9):3125-3136.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714	S3226	S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC77387	AUR1545	AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).
DC77822	JNJ-77242113 (Icotrokinr)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
DC77088	T025	T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.